| L01FX15 |
L01FX15 Belantamab mafodotin |
| L01FX16 |
L01FX16 Oportuzumab monatox |
| L01FX17 |
L01FX17 Sacituzumab govitecan |
| L01FX18 |
L01FX18 Amivantamab |
| L01FX19 |
L01FX19 Sabatolimab |
| L01FX20 |
L01FX20 Trémélimumab |
| L01FX21 |
L01FX21 Naxitamab |
| L01FX22 |
L01FX22 Loncastuximab tesirine |
| L01FX23 |
L01FX23 Tisotumab vedotin |
| L01FX24 |
L01FX24 Teclistamab |
| L01FX25 |
L01FX25 Mosunetuzumab |
| L01FX26 |
L01FX26 Mirvetuximab soravtansine |
| L01FX27 |
L01FX27 Epcoritamab |
| L01FX28 |
L01FX28 Glofitamab |
| L01FX29 |
L01FX29 Talquetamab |
| L01FX31 |
L01FX31 Zolbetuximab |
| L01FX32 |
L01FX32 Elranatamab |
| L01FX33 |
L01FX33 Tarlatamab |
| L01FX34 |
L01FX34 Odronextamab |
| L01FX35 |
L01FX35 Datopotamab deruxtecan |
| L01FX36 |
L01FX36 Patritumab deruxtecan |
| L01FY |
L01FY Combinations of monoclonal antibodies and antibody drug conjugates |
| L01FY01 |
L01FY01 Pertuzumab and trastuzumab |
| L01FY02 |
L01FY02 Nivolumab and Relatlimab |
| L01FY03 |
L01FY03 Prolgolimab and Nurulimab |
| L01X |
L01X Other antineoplastic agents |
| L01XA |
L01XA Platinum compounds |
| L01XA01 |
L01XA01 Cisplatin |
| L01XA02 |
L01XA02 Carboplatin |
| L01XA03 |
L01XA03 Oxaliplatin |